Cited by 284Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 20 of the 22 references it cites were found in a registry or an index.

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Open access

Lu, Shun, Wang, Jie, Yu, Yan, Yu, Xinmin, Hu, Yanping, Ai, Xinghao, Ma, Zhiyong, Li, Xingya, Zhuang, Wu, Liu, Yunpeng, Li, Weidong, Cui, Jiuwei, Wang, Dong, Liao, Wangjun, Zhou, Jianying, Wang, Zhehai, Sun, Yuping, Qiu, Xiusong, Gao, Jie, Bao, Yuanyuan, Liang, Liang, Wang, Mengzhao·2021·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2021.05.005

Open this paper in CoChat — free account Open PDF

Abstract

INTRODUCTION: Tislelizumab, an anti-programmed cell death protein-1 antibody, was specifically engineered to minimize FcɣR macrophage binding to abrogate antibody-dependent phagocytosis. Compared with chemotherapy alone, tislelizumab plus chemotherapy may improve clinical outcomes in patients with advanced nonsquamous NSCLC (nsq-NSCLC). METHODS: In this open-label phase 3 trial (RATIONALE 304; NCT03663205), patients with histologically confirmed stage IIIB or IV nsq-NSCLC were randomized (2:1) to receive either arm A: tislelizumab plus platinum (carboplatin or cisplatin) and pemetrexed every 3 weeks (Q3Ws) or arm B: platinum and pemetrexed alone Q3W during induction treatment, followed by intravenous maintenance pemetrexed Q3W. The primary end point was progression-free survival (PFS) assessed by an independent review committee; clinical response and safety and tolerability were secondary end points. RESULTS: Overall, 332 patients (n = 222 [A]; n = 110 [B]) received treatment. With a median study follow-up of 9.8 months, PFS was significantly longer with tislelizumab plus chemotherapy compared with chemotherapy alone (median PFS: 9.7 versus 7.6 mo; hazard ratio = 0.645 [95% confidence interval: 0.462-0.902], p = 0.0044). In addition, response rates were higher and response duration was longer with combination therapy versus chemotherapy alone. Hematologic adverse events (AEs) were common in both treatment arms; the most reported AEs were grades 1 to 2 in severity. The most common grade greater than or equal to 3 AEs were associated with chemotherapy and included neutropenia (44.6% [A]; 35.5% [B]) and leukopenia (21.6% [A]; 14.5% [B]). CONCLUSIONS: Addition of tislelizumab to chemotherapy resulted in significantly prolonged PFS, higher response rates, and longer response duration compared with chemotherapy alone, identifying a new potential option for first-line treatment of advanced nsq-NSCLC irrespective of disease stage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.05.005

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citation
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E. I., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 418
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2160-x · Cited by 294
Self-citation
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Shen, L., Guo, J., Zhang, Q., Pan, H., Yuan, Y., Bai, Y., Liu, T., Zhou, Q. H., Zhao, J., Shu, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000437 · Cited by 154
Self-citation

Flagged first, then by citations

Show all 22 references

2 of the 22 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–284 of 284

Low-Dose Intestinal Irradiation Enhances the Efficacy and Prognosis of PD-1 Blockade in Metastatic Non–Small Cell Lung Cancer
Huang, B.-Y., Zhao, J.-R., Zhu, J.-Y., Wang, X.-P., Li, M., Xu, J., Wang, K.-Y., Wang, X.-H., Wang, W., Bo, C., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4153 · Cited by 2
Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma
Chen, P., Wang, M., Peng, S., Zhu, H., Wang, Y., Wan, Z., Yang, X., Yu, Z., & Zhou, Y. (2026) · Current Oncology · doi:10.3390/curroncol33030173 · Cited by 1
Self-citation
Efficacy of first-line treatment in driver gene-negative non-small cell lung cancer with liver metastases: a Bayesian network meta-analysis
Wu, W., Guo, X., Dong, X., Liang, H., & Zhang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1791664 · Cited by 1
800 Clinicopathological and molecular predictive factors of survival in non-small cell lung cancer patients treated with first-line immunotherapy with or without chemotherapy: a systematic review and meta-analysis
Federico, A. D., Gelsomino, F., Giglio, A. D., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.0800 · Cited by 1
Efficacy and Safety of Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People’s Republic of China: a Systematic Review and Meta-Analysis
Chen, Q., Ma, K., Zhang, L., Lin, W., Wu, X., & Gao, Y. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100678 · Cited by 1
A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review
Liu, Y., Li, M., Guo, Y., Zhang, Z., Du, L., Zhang, X., Wang, Y., Zhang, D., Xue, L., Lei, B., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155371 · Cited by 1
Self-citation
Study on PD-1 inhibitor combined with recombinant human endostatin and chemotherapy followed by IMRT in the treatment of advanced NSCLC
Fa-qiang, M., Qi, Z., Liao, G., Zhao, L., Su, X., Dong, C., Lu, F., & Sun, Y. (2025) · Medicine · doi:10.1097/md.0000000000041306 · Cited by 1
Self-citation
The clinicopathologic characteristics and tumor immune microenvironment of pulmonary enteric adenocarcinoma
Yang, L., Chen, L., Gong, J., & Lu, H. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2519675 · Cited by 1
SOTA: A statistical tool for quantifying the superiority onset time of PD-1/PD-L1 inhibitor response based on Kaplan–Meier graphics and its application in a meta-analysis of NSCLC randomized controlled trials
Fan, Q., Wang, X., Wang, Y., Xu, X., Cao, Q., Li, Y., Zhao, Y., Shao, F., Jiang, Q., Wang, M., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003733 · Cited by 1
Self-citation
Breaking barriers: Pembrolizumab's role in overcoming targeted therapy resistance in BRAF-mutant melanoma
Idris, O. A., Shebrain, A., Jawad, A., Pacione, S. C., Haj, D., Bzizi, H. F., Ahmedfiqi, Y. O., Jahromi, B. S., Deleon, N., Zhang, T., et al. (2025) · Clinical Surgical Oncology · doi:10.1016/j.cson.2025.100095 · Cited by 1
The impact of immune checkpoint inhibitors on cost and quality of life in the initial treatment of patients with advanced or metastatic NSCLC
Procailo, K. M. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88770 · Cited by 1
Winds From the ORIENT: New Data to Inform RATIONAL Choice?
Bironzo, P., Passiglia, F., & Novello, S. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.003
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisPreprint
Chen, C.-Y., Huang, C., Chen, W., Huang, M., & Wei, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-1168265/v1
Traitement de 1re ligne des CBNPC métastatiques sans addiction oncogénique
Pérol, M. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00014-3
Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study
Li, Y., Yang, P., Zhou, X., Yang, X., & Wu, S. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.954490
A GLOBAL CONGRESS DIGEST ON SOLID TUMORS. Report from the ASCO Hybrid Congress , 3rd – 7th June 2022
(2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00836-3
Poor efficacy of immune checkpoint inhibitors plus chemotherapy in the lung cancer patients with EGFR/ERBB2 exon 20 insertionPreprint
Fu, Y., Zheng, Y., Chen, Y., Wang, P., Li, Q., Liu, T., & Ding, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1911438/v1
Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges
Hosseini, M., & Rezaei, N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_52
Gender is a non-negligible risk factor affecting the overall survival time of NSCLC patients: a nationwide population-based studyPreprint
Liang, L., Wang, B., Wang, C., & Xie, S. (2023) · Research Square · doi:10.21203/rs.3.rs-2382536/v1
Self-citation
DNA aptamers target PD-L1 and conjugate gemcitabine as a novel therapeutic strategy α β γ chemotherapy combined with immunotherapy for bladder cancer....Preprint
Hu, X., Zeng, H., Peng, Y., Deng, M., Xiang, W., Liu, B., Liu, J., Fu, Y., Hu, Z., Hou, W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2976453/v1
Research Status and Prospect of Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer
于, 楠. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381762
Progress of Immune Checkpoint Inhibitors as First-Line Monotherapy and Combined Chemotherapy for Advanced Non-Small Cell Lung Cancer with Negative Driver Genes
张, 学. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381815
Role of ICIs-Based Therapies and Bevacizumab for Advanced Wild-Type Non-Squamous NSCLC in the First-Line Setting: A Bayesian Network AnalysisPreprint
Yang, S., Lingling, Z., Xu, W., Jinmin, X., & Yuxi, Z. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4571985
Economics of First-line Treatment with Tislelizumab in Patients with Nonsquamous Non-small Cell Lung Cancer: A Four-state Markov ModelPreprint
Wang, L., Liu, T., Lin, X., Zhang, Y., Shi, L., You, R., & Liu, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4021069/v1
Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review
Ma, Y., Shi, X., Zhao, K., Hu, S., Shi, Y., Jiang, Y., Liu, Y., Lu, L., Chang, Y., Zhou, F., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1328844
Self-citation
The Efficacy and Toxicity of Maintenance Therapy with Pd-1/Pd-L1 Inhibitors Plus Pemetrexed Versus Immunotherapy Alone for Stage Iii/Iv Non-Squamous Non-Small Cell Lung Cancer: A Real World StudyPreprint
Huang, Z., Mei, S., Liu, J., Zhang, Q., Chang, J., Li, Z., Xu, J., Luo, W., Lu, C., Zhang, C.-Y., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4836830
A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC
Xing, T. Y., Gao, Q., Zhu, H., Gao, J., & Yan, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1402018
Self-citation
Significance of Immune Checkpoints in Lung Cancer
Dimou, A., & Leventakos, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_9
Clinical prognostic factors for the effectiveness of immunotherapy in patients with unresectable NSCLC
Krasavina, M. A., Artemieva, E. V., Жабина, А. С., Belukhin, S. A., Макаркина, М. Л., Agranov, I. R., Elsakova, E., Oganesian, A. P., Kheinstein, V. A., Волков, Н. М., et al. (2024) · Practical oncology · doi:10.31917/2502154
WITHDRAWN: Efficacy and safety of bronchial arterial chemoembolization in combination with tislelizumab for non-small cell lung cancer: a phase II studyPreprint
Liang, C., Han, D., Li, H., Wang, M., Kuang, D., Chen, P., Lu, H., Jiao, P., Ren, J., Xinwei, H., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5026061/v1
Self-citation
Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS
Pang, J., Zhang, Y., Wang, X., Wu, W., Wan, C., Li, Z., & Du, Y. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108001
Determining optimal clinical target volume margins based on microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer after chemotherapy or chemotherapy combined with immunotherapy
Zhang, Y., Li, J., Song, X., Zhao, F., Li, L., & Yuan, S. (2024) · BMC Cancer · doi:10.1186/s12885-024-13135-3
Lymphoma combined with lung cancer: A case report
Zhang, D., Liang, J., Lv, Y., Huang, X., & Guo, W. (2024) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2024.102140
Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study
Huang, Y., Ding, P., Zhang, R., Zhang, Y., Tong, F., Cheng, S., Peng, L., Jie, X., Wang, J., Liu, P., et al. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.02.007
Self-citation
Research Progress of Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
丽, 梅. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153732
Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non–Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score–Matched Analysis
Marimuthu, P. K., Georgy, J. T., Philip, D. S. J., John, A. O., Joel, A., Thumaty, D. B., Chacko, R. T., Jambunathan, P., Thomas, Z., Harikrishna, K., et al. (2025) · JCO Global Oncology · doi:10.1200/go-24-00256
Efficacy of immunotherapy remained in patients with recurrent/metastatic non‐small‐cell lung cancer after surgery with or without postoperative thoracic radiotherapy: a bi‐center retrospective study
Wu, Y., Li, R., Tan, F., Cao, J., & Bi, N. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.15384
Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
Kant, R., Roy, P., Kaur, A., & Kumar, R. (2025) · Journal of Coloproctology · doi:10.1055/s-0045-1809675
Treatment patterns and clinical outcomes in Chinese patients with NSCLC with MET alterations resistant to EGFR‑TKI therapy
Shen, C., Zhang, S., Wang, X., Shen, D., Ge, X., & Mao, Y. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2876
WITHDRAWN: Efficacy and safety of bronchial arterial chemoembolization in combination with tislelizumab for non-small cell lung cancer: a phase II studyPreprint
Liang, C., Han, D., Li, H., Wang, M., Kuang, D., Chen, P., Lu, H., Jiao, P., Ren, J., Xinwei, H., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5026061/v2
Self-citation
Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 <1% metastatic non-small-cell lung cancer – implications for daily clinical practice
Bryl, M., Stencel, K. M., Knetki‐Wróblewska, M., & Krzakowski, M. J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2557610
Sunvozertinib Monotherapy in Advanced Lung Adenocarcinoma with EGFR Exon 20 Insertion and High PD-L1 Expression: A Case Report
Zhou, J., & Han, H. (2025) · Cancer Management and Research · doi:10.2147/cmar.s524920
Self-citation
Comparative safety and efficacy of tislelizumab-based regimens versus chemotherapy in lung cancer: a systematic review and meta-analysis
Ullah, A., Haider, F., Ahmed, F., Arham, M., Dad, A., Tareen, H. K., Saleem, F., Bakht, K., Malik, A. N., Afzaal, Z., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1628742
Efficacy and safety of tislelizumab in the treatment of non-small cell lung cancer: A meta-analysis of randomized controlled trials
Liu, Y., Huang, W., Meng, W., & Xiang, Y. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.09.020
Self-citation
Tislelizumab in conjunction with chemotherapy for the treatment of nasal metastasis from lung squamous cell carcinoma: a case report and literature review
Luo, K., Dai, L., Lin, K., Zhang, H., Pi, K., Yang, N., Gao, Y., Yu, J., Wu, J., & Xiao, Q. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251384018
Current landscape of cross-line immune checkpoint blockade for cancer treatment
Fan, P., Wu, K., Zhu, C., & Guan, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218135
Efficacy of PD-1 inhibitor plus chemotherapy and bevacizumab in initial therapy of metastatic non-squamous non-small cell lung cancer with driver gene negativity: A real-world retrospective study
Cong, J., Wang, A., Wang, Y., Pi, J., Liu, K., & Li, H. (2025) · Medicine · doi:10.1097/md.0000000000044157
Additional file 1 of Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach
Hui, W., Song, R., Tao, H., Gao, Z., Zhu, M., Zhang, M., Wu, H., Gong, D., Zhang, X., & Cai, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22826938
Additional file 2 of Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study
Wei, Q., Deng, T., Wu, J., Zeng, H., Qi, C., Tan, S., Zhang, Y., Huang, Q., Pu, X., Xu, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25506741
Self-citation
Additional file 1 of Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Zhang, Y., Song, L., Zeng, L., Xiong, Y., Liu, L., Zhou, C., Yang, H., Wang, Z., Xia, Q., Jiang, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20962512
Self-citation
Additional file 1 of Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study
Wei, Q., Deng, T., Wu, J., Zeng, H., Qi, C., Tan, S., Zhang, Y., Huang, Q., Pu, X., Xu, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25506638
Self-citation
Additional file 1 of The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials
Daei Sorkhabi, A., ZareDini, M., Fazlollahi, A., Sarkesh, A., Naseri, A., Mousavi, S. E., Nejadghaderi, S. A., Sullman, M. J. M., Kolahi, A.-A., & Safiri, S. (2023) · Figshare · doi:10.6084/m9.figshare.24779175
Additional file 1 of Time-dependent efficacy analysis of first-line immunotherapies for advanced non–small cell lung cancer
Hui, W., Li, W., Song, R., Xin, Y., Wu, C., Gao, Z., Zhang, M., Wu, H., Zhu, M., & Cai, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25980474
Self-citation
Myristicin inhibits the progression of non-small cell lung cancer by deactivating the Wnt/β-catenin pathway
Jing, C., Cao, H., Wang, Z., Yu, Y., Li, B., & Ma, R. (2026) · Cytotechnology · doi:10.1007/s10616-026-00893-0
Self-citation
Impact of pre-therapeutic fasting plasma glucose on survival outcomes in advanced non-small cell lung cancer patients
Liu, F., Luo, M., Wang, F., Liang, T., & Wang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630503
Bronchial Arterial Chemoembolization Combined with Tislelizumab for Non–Small Cell Lung Cancer: An Exploratory, Prospective, Single-Arm, Phase II Trial
Liang, C., Han, D., Li, H., Wang, M., Kuang, D., Chen, H., Miao, H., Chen, P., Lu, H., Jiao, P., et al. (2026) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2026.108001
Self-citation
Tislelizumab—Current Status and Future Directions: A Review Article
Basu, P. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1816551
Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study
Zeng, L., Xiang, Y., Sun, A., & Lu, K. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1718151
Response characteristics of tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-Small cell lung cancerPreprint
Cai, L., Wang, Y., Fan, C., Hong, K., & Qiu, A. (2026) · Research Square · doi:10.21203/rs.3.rs-8627031/v1
Immunochemotherapy combined with surgery in oligometastatic non-small cell lung cancer: a retrospective studyPreprint
Li, Z., Mao, Y., Gao, Z., Shao, C., Qiao, W., Duan, H., & Yan, X. (2026) · Research Square · doi:10.21203/rs.3.rs-8684499/v1
Nicht-kleinzelliges Lungenkarzinom: Ist geschlechtsspezifische Immuntherapie nötig?
Krieghoff‐Henning, E., Collienne, M., & Loges, S. (2026) · Forum · doi:10.1007/s12312-026-01555-0
Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer
Wu, D., Cui, J., Zhum, W., Qin, T., & Xu, H. (2026) · ONCOLOGY · doi:10.46883/2026.25921065
Self-citation
Diagnostik und Therapie des lokal fortgeschrittenen inoperablen NSCLC
Möller, M., & Vordermark, D. (2026) · Zeitschrift für Pneumologie · doi:10.1007/s10405-026-00671-x
Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs. immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world study
Huang, Z., Mei, S., Liu, J. I. N., Zhang, Q., Chang, J.-H., Li, Z.-H., Xu, J.-Y., Luo, W., Lu, C., Zhang, M., et al. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004083
The efficacy and safety of four different PD-1 checkpoint inhibitors in advanced non-small cell lung cancer: a real-world retrospective study
Wang, H., Xing, Z., Ren, X., Bai, R., Zou, Y., Wang, Y., Zhang, H., & Zhang, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1833634
Clinical exploration of first-line therapy in metastatic lung adenocarcinoma patients with negative or low PD-L1 expression: a retrospective cohort study
Xu, K., Cai, R., Sun, Z., Wang, C., & Bao, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1836760
Comparative efficacy of Chinese-developed versus imported PD-1/PD-L1 inhibitors in first-line combination therapy for advanced NSCLC: a systematic review and network meta-analysis
Yang, J., Min, R., Zhong, H., Li, C., & Hu, Y. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.06.002
Self-citation
Programmed-death 1/programmed-death ligand 1 inhibitors plus chemotherapy versus chemotherapy for first-line treatment of advanced driver-gene negative non-squamous non-small cell lung cancer: An updated systematic review and meta-analysis
Zhao, Z., Shi, W., Yu, M., & Cheng, X. (2026) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_225_24
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma
Garralda, E., Schöffski, P., Oberoi, A., Schüler, M., Richly, H., Ascierto, P. A., Lin, C. Y., Alvarez, R. M., Patel, S. P., Xing, Y., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116899
Clinical outcomes of concomitant anti-PD-1 therapy and denosumab treatment in non-small cell lung cancer patients with bone metastasis: a single-center retrospective study
Fu, M., Liu, N., Qu, J., Shen, Q., Zheng, J., Li, Y., Zhou, J., & Zhou, J. (2026) · Discover Oncology · doi:10.1007/s12672-026-05373-7
Self-citation
Efficacy and safety of Programmed Death Ligand 1 inhibitors versus Programmed Death 1 inhibitors in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials
Dang, C., Li, J., Chen, H., & Luo, Z. (2026) · PeerJ · doi:10.7717/peerj.21402
Efficacy and Safety Analysis of Camrelizumab, Sintilimab, and Tislelizumab in the Treatment of NSCLC in Xuanwei, China: A Retrospective Real-World StudyPreprint
Long, F., He, J., Pan, X., Li, J., Liu, X. R., Lu, S., Wang, X. L., & Kong, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9373929/v1
Self-citation
The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and meta-analysis
Jiang, Q., Liu, J., Li, Z., Zhang, C., Dang, Q., & Tian, Y. (2026) · Medicine · doi:10.1097/md.0000000000049720
Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety
Quan, Y., Liang, Z., Wei, Y., Li, H., Zeng, Y., Shen, J., Su, S., Liu, X., Huang, Z., Wang, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1786284
Self-citation
Exploratory safety analysis of tislelizumab-based regimens in patients with lung cancer: a retrospective real-world study
Liu, J., Zhang, Q., Lin, X., Nuo, Y., & You, R. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04540-4
Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis
Kumar, J., Ganguly, S., Kaur, P., Raghav, A., Pai, K., Meena, J., Goyal, J. P., & Yadav, J. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_3200_2025
Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: a single-center retrospective study
Mo, W., Li, Y., Zhao, L., Liu, Y., Shu, Q., & Fei, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1898071
Self-citation
Optimizing PD-1/PD-L1 inhibitors plus chemotherapy for driver mutation–negative non-squamous NSCLC in China: a cost-effectiveness analysis
Ji, J., Du, Q., Teng, M., Qin, F., Zhang, R., & Dong, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1849145
Mythologization of statistics in biomedical research
Slavenko, M. G., Mironenko, O. N., Kuznetsov, M., & Bakin, E. A. (2026) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2026-54-010
Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations
Zhang, Q., Qin, Z., & Guo, C. (2026) · MedComm – Oncology · doi:10.1002/mog2.70097
The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective
Waissengrin, B., Tagliamento, M., Sankar, K. N., & Reckamp, K. L. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103957
No Overall Survival Benefit with Adding Chemotherapy to Immunotherapy in PD-L1 TPS ≥ 50% NSCLC: An Agent-Stratified ReassessmentPreprint
Han, F., Wang, J., Shi, S., Jin, M., & Ren, C. (2026) · medRxiv · doi:10.64898/2026.09.01.26361919
Self-citation
An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C–IV non-squamous NSCLC
Li, S., Du, F., Leng, C., Dou, J., Shi, J., Zhang, Y., Lu, F., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1854773
Comparative efficacy and safety of protocol-defined 2-year versus indefinite immunotherapy strategies for advanced non-small-cell lung cancer: A systematic review and network meta-analysis
Jiamei, Y. U., Ling, Q., Jiao, Y., Ni, S., Zhao, T., Zhang, X., Jiang, Y., 孟丽娟, & Liu, L. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261499452

Authors: Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., Li, W., Cui, J., Wang, D., Liao, W., Zhou, J., Wang, Z., Sun, Y., Qiu, X., Gao, J., Bao, Y., Liang, L., & Wang, M.
Affiliations: Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Third Affiliated Hospital of Harbin Medical University (CN)
Zhejiang Cancer Hospital (CN)
Hubei Cancer Hospital (CN)
Shanghai Chest Hospital (CN)
Zhengzhou University (CN)
First Affiliated Hospital of Zhengzhou University (CN)
Fujian Provincial Cancer Hospital (CN)
First Hospital of China Medical University (CN)
Guangzhou Medical University Cancer Hospital (CN)
First Hospital of Jilin University (CN)
Army Medical University (CN)
Nanfang Hospital (CN)
First Affiliated Hospital Zhejiang University (CN)
Shandong Tumor Hospital (CN)
Jinan Central Hospital (CN)
BeiGene (China) (CN)
Peking Union Medical College Hospital (CN)
ORCID: Lu, Shun
Wang, Jie
Yu, Yan
Hu, Yanping
Ma, Zhiyong
Li, Xingya
Zhuang, Wu
Liu, Yunpeng
Li, Weidong
Cui, Jiuwei
Wang, Dong
Liao, Wangjun
Zhou, Jianying
Wang, Zhehai
Gao, Jie
Liang, Liang
Wang, Mengzhao
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2021-09
Volume: 16
Issue: 9
Pages: 1512-1522
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2021.05.005
OpenAlex: W3164993995
Cited by: 284
References: 22
Citations by year: 2026: 41 · 2025: 59 · 2024: 57 · 2023: 62 · 2022: 54 · 2021: 11
FWCI: 29.83
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Roche
Boehringer Ingelheim
AstraZeneca
BeiGene
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: tislelizumab, non-squamous non-small cell lung cancer, first-line therapy, anti-PD-1 therapy, progression-free survival, Fcγ receptor binding, antibody-dependent phagocytosis, locally advanced or metastatic NSCLC, neutropenia, leukopenia
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks